[go: up one dir, main page]

MA40111A1 - Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 - Google Patents

Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1

Info

Publication number
MA40111A1
MA40111A1 MA40111A MA40111A MA40111A1 MA 40111 A1 MA40111 A1 MA 40111A1 MA 40111 A MA40111 A MA 40111A MA 40111 A MA40111 A MA 40111A MA 40111 A1 MA40111 A1 MA 40111A1
Authority
MA
Morocco
Prior art keywords
protein
tetrahydronaphthalene
derivatives
compounds
inhibiting mcl
Prior art date
Application number
MA40111A
Other languages
English (en)
Other versions
MA40111B1 (fr
Inventor
Sean P Brown
Yunxiao Li
Mike Elias Lizarzaburu
Brian S Lucas
Nick A Paras
Joshua Taygerly
Marc Vimolratana
Xianghong Wang
Ming Yu
Manuel Zancanella
Liusheng Zhu
Buenrostro Ana Gonzalez
Zhihong Li
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA40111A1 publication Critical patent/MA40111A1/fr
Publication of MA40111B1 publication Critical patent/MA40111B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/11—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des inhibiteurs de la protéine de la leucémie myéloïde 1 (mcl-1), leurs procédés de préparation, des compositions pharmaceutiques associées, et leurs méthodes d'utilisation. L'invention concerne, par exemple, de composés de formule (i) et des sels pharmaceutiquement acceptables de ceux-ci, ainsi que des compositions comprenant ces composés. Les composés et les compositions de l'invention peuvent être utilisés, par exemple, dans le traitement de maladies ou affections telles que le cancer.
MA40111A 2014-08-29 2015-08-28 Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 MA40111B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462043929P 2014-08-29 2014-08-29
PCT/US2015/047472 WO2016033486A1 (fr) 2014-08-29 2015-08-28 Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1

Publications (2)

Publication Number Publication Date
MA40111A1 true MA40111A1 (fr) 2018-06-29
MA40111B1 MA40111B1 (fr) 2018-12-31

Family

ID=54238507

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40111A MA40111B1 (fr) 2014-08-29 2015-08-28 Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1

Country Status (41)

Country Link
US (7) US9562061B2 (fr)
EP (2) EP3186259B1 (fr)
JP (1) JP6502479B2 (fr)
KR (1) KR102466351B1 (fr)
CN (1) CN107001387B (fr)
AP (1) AP2017009827A0 (fr)
AR (1) AR101729A1 (fr)
AU (1) AU2015308735B2 (fr)
BR (1) BR112017004209B1 (fr)
CA (1) CA2959615C (fr)
CL (1) CL2017000469A1 (fr)
CO (1) CO2017002998A2 (fr)
CR (1) CR20170116A (fr)
CY (1) CY1121195T1 (fr)
DK (1) DK3186259T3 (fr)
EA (1) EA031223B1 (fr)
ES (2) ES2706309T3 (fr)
HR (1) HRP20190053T1 (fr)
HU (1) HUE041806T2 (fr)
IL (2) IL250843B (fr)
JO (1) JO3474B1 (fr)
LT (1) LT3186259T (fr)
MA (1) MA40111B1 (fr)
ME (1) ME03313B (fr)
MX (1) MX379155B (fr)
MY (1) MY176235A (fr)
PE (1) PE20170892A1 (fr)
PH (1) PH12017500367A1 (fr)
PL (1) PL3186259T3 (fr)
PT (1) PT3186259T (fr)
RS (1) RS58276B1 (fr)
SG (1) SG11201701525WA (fr)
SI (1) SI3186259T1 (fr)
SM (1) SMT201900048T1 (fr)
TN (1) TN2017000067A1 (fr)
TR (1) TR201901312T4 (fr)
TW (1) TWI676628B (fr)
UA (1) UA118233C2 (fr)
UY (1) UY36285A (fr)
WO (1) WO2016033486A1 (fr)
ZA (2) ZA201701763B (fr)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
WO2017147410A1 (fr) * 2016-02-25 2017-08-31 Amgen Inc. Composés inhibant la protéine mcl-1
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
EP3455219A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de c3-glutarimide liés à une amine pour la dégradation de protéines cibles
ES2990061T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros espirocíclicos para la degradación de proteínas diana
WO2017197046A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
UY37342A (es) 2016-07-22 2018-01-31 Servier Lab Combinación de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacéuticas de éstos
JP6453507B2 (ja) 2017-03-30 2019-01-16 アムジエン・インコーポレーテツド Ｍｃｌ−１タンパク質を阻害する化合物
WO2018237026A1 (fr) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. Dégrons et dégronimères à liaison n/o pour la dégradation de protéines
WO2019035927A1 (fr) * 2017-08-15 2019-02-21 Abbvie Inc. Inhibiteurs de mcl-1 macrocyclique et procédés d'utilisation
CA3073112A1 (fr) * 2017-08-15 2019-02-21 Abbvie Inc. Inhibiteurs macrocycliques de mcl-1 et methodes d'utilisation
MA49908A (fr) 2017-08-18 2021-04-28 Amgen Inc Composés inhibant la protéine mcl-1
US11279712B2 (en) 2017-08-29 2022-03-22 Amgen Inc. Macrocyclic compounds that inhibit MCL-1 protein
WO2019173181A1 (fr) * 2018-03-05 2019-09-12 Amgen Inc. Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1
CN117304130A (zh) * 2018-05-14 2023-12-29 吉利德科学公司 Mcl-1抑制剂
MA54157A (fr) * 2018-11-09 2021-09-15 Prelude Therapeutics Inc Dérivés de spiro-sulfonamide en tant qu'inhibiteurs de la protéine de la leucémie myéloïde -1 (mcl-1)
EP3897631A4 (fr) 2018-12-20 2022-11-23 C4 Therapeutics, Inc. Dégradation ciblée de protéines
EP3781574B1 (fr) * 2019-01-18 2023-05-10 Ascentage Pharma (Suzhou) Co., Ltd. Spiroéthers macrocycliques utilisés en tant qu'inhibiteurs de mcl-1
AU2020279979A1 (en) 2019-05-20 2021-11-25 Les Laboratoires Servier Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2020237025A1 (fr) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Exo-méthylène-oxindoles substitués qui sont des inhibiteurs de hpk1/map4k1
KR20220024694A (ko) * 2019-06-21 2022-03-03 얀센 파마슈티카 엔.브이. Mcl-1의 거대환식 억제제
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
CA3144558A1 (fr) 2019-07-09 2021-01-14 Janssen Pharmaceutica Nv Derives de spirocycles macrocycliques en tant qu'inhibiteurs de mcl-1
EP3771469A1 (fr) 2019-07-30 2021-02-03 Amgen, Inc Formulations et dosages pour l'administration d'un composé inhibant la protéine mcl1
CN112479876B (zh) * 2019-09-12 2023-07-21 苏州亚盛药业有限公司 氧氮杂环庚烷类螺环化合物、中间体及其制备方法
ES2973832T3 (es) 2019-10-18 2024-06-24 Forty Seven Inc Terapias combinadas para el tratamiento de síndromes mielodisplásicos y leucemia mieloide aguda
AU2020374947C1 (en) 2019-10-31 2025-05-08 Forty Seven, LLC Anti-CD47 and anti-CD20 based treatment of blood cancer
CN120699039A (zh) * 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
WO2021091982A1 (fr) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Inhibiteurs de ras
TWI778443B (zh) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1抑制劑
SI4065567T1 (sl) * 2019-11-26 2025-01-31 Gilead Sciences, Inc. Postopki in intermediati za pripravo inhibitorjev mcl1
IL294032A (en) 2019-12-24 2022-08-01 Carna Biosciences Inc Compounds that regulate diacylglycerol kinase
EP4103285A2 (fr) 2020-02-14 2022-12-21 Jounce Therapeutics, Inc. Anticorps et protéines de fusion se liant à ccr8, et leurs utilisations
CN115151551B (zh) * 2020-02-21 2024-10-25 詹森药业有限公司 作为mcl-1抑制剂的大环吲哚衍生物
JP2021161114A (ja) * 2020-03-31 2021-10-11 アムジエン・インコーポレーテツド Ｍｃｌ−１化合物のメチル化
US20230212191A1 (en) * 2020-04-16 2023-07-06 Prelude Therapeutics, Incorporated Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein
JP7564888B2 (ja) 2020-05-01 2024-10-09 ギリアード サイエンシーズ， インコーポレイテッド Ｃｄ７３阻害性２，４－ジオキソピリミジン化合物
TWI827924B (zh) * 2020-05-06 2024-01-01 美商安進公司 大環Mcl-1抑制劑中間體的閉環合成
US12441681B2 (en) 2020-05-06 2025-10-14 Amgen Inc. Synthesis of sulfonamide intermediates
AU2021268569B2 (en) * 2020-05-06 2024-06-13 Amgen Inc. Synthesis of vinylic protected alcohol intermediates
TWI867217B (zh) * 2020-05-06 2024-12-21 美商安進公司 乙烯基環丁基中間體之合成
WO2021225835A1 (fr) * 2020-05-06 2021-11-11 Amgen Inc. Synthèse d'intermédiaires d'alcool vinylique
CA3180387A1 (fr) * 2020-06-10 2021-12-16 Soufyan JERHAOUI 2-amino-3-fluoro-but-3-enamides macrocycliques utilises comme inhibiteurs de mcl-1
US20230365588A1 (en) * 2020-09-03 2023-11-16 Amgen Inc. Diol desymmetrization by nucleophilic aromatic substitution
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
CN120590359A (zh) * 2020-11-19 2025-09-05 吉利德科学公司 用于制备大环mcl1抑制剂的方法和中间体
CN117136076A (zh) 2020-11-24 2023-11-28 诺华股份有限公司 Mcl-1抑制剂抗体药物缀合物和使用方法
WO2022115400A1 (fr) * 2020-11-25 2022-06-02 Amgen Inc. Alcénylation énantiosélective d'aldéhydes
EP4008324A1 (fr) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinaisons comprenant un inhibiteur d'une protéine anti-apoptotique, telle que bcl-2, bcl-xl, bclw ou mcl-1, et un inhibiteur de voie de signalisation notch pour le traitement du cancer
US20240041884A1 (en) 2020-12-07 2024-02-08 Cellestia Biotech Ag Pharmaceutical Combinations for Treating Cancer
ES3026771T3 (en) 2020-12-17 2025-06-12 Janssen Pharmaceutica Nv Macrocyclic branched 3-fluoro-but-3-enamides as inhibitors of mcl-1
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
BR112023020877A2 (pt) 2021-04-26 2023-12-12 Janssen Pharmaceutica Nv 2-aliltetra-hidrofuranos macrocíclicos como inibidores de mcl-1
CR20230558A (es) 2021-05-05 2024-01-24 Revolution Medicines Inc Inhibidores de ras para el tratamiento del cáncer
US20220389394A1 (en) 2021-05-18 2022-12-08 Gilead Sciences, Inc. METHODS OF USING FLT3L-Fc FUSION PROTEINS
JP2024520801A (ja) 2021-06-11 2024-05-24 ギリアード サイエンシーズ， インコーポレイテッド Ｍｃｌ－１阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
EP4359413A1 (fr) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Composés de modulation de la diacylglycérol kinase
CA3220923A1 (fr) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Composes de modulation de la diacylglycerol kinase
CN117355531A (zh) 2021-06-23 2024-01-05 吉利德科学公司 二酰基甘油激酶调节化合物
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
JP2024539252A (ja) 2021-10-28 2024-10-28 ギリアード サイエンシーズ， インコーポレイテッド ピリジジン－３（２ｈ）－オン誘導体
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
US20250051359A1 (en) 2021-11-16 2025-02-13 Janssen Pharmaceutica Nv Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1
WO2023107956A1 (fr) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Protéines se liant à nkg2d, cd16 et 5t4
US20230220106A1 (en) 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
JP2024546851A (ja) 2021-12-22 2024-12-26 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
CA3237577A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de degradation des doigts de zinc de la famille ikaros et leurs utilisations
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
PL4245756T3 (pl) 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
AU2023250874A1 (en) * 2022-04-05 2024-10-10 Amgen Inc. Amorphous and crystalline forms of mci-1 antagonists
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
JP2025513774A (ja) 2022-04-05 2025-04-30 アムジエン・インコーポレーテツド Ｍｃｌ－１アンタゴニストの塩形態及び溶媒和物
CA3249472A1 (fr) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Composés modulateurs de virus du sarcome de rat de kirsten g12d
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
AU2023298558A1 (en) 2022-07-01 2024-12-19 Gilead Sciences, Inc. Cd73 compounds
WO2024064668A1 (fr) 2022-09-21 2024-03-28 Gilead Sciences, Inc. POLYTHÉRAPIE ANTICANCÉREUSE PAR RAYONNEMENT IONISANT FOCAL ET PERTURBATION CD47/SIRPα
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
CN120882725A (zh) 2023-04-11 2025-10-31 吉利德科学公司 Kras调节化合物
KR20250175331A (ko) 2023-04-21 2025-12-16 길리애드 사이언시즈, 인코포레이티드 Prmt5 억제제 및 이의 용도
AU2024306338A1 (en) 2023-06-30 2026-01-08 Gilead Sciences, Inc. Kras modulating compounds
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025024811A1 (fr) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Inhibiteurs de parp7
EP4516807A1 (fr) 2023-08-28 2025-03-05 Consorcio Centro de Investigación Biomédica en Red Compositions destinées à être utilisées dans un procédé de fourniture d'une greffe améliorée de cellules souches hématopoïétiques
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250154172A1 (en) 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025111431A1 (fr) 2023-11-22 2025-05-30 Les Laboratoires Servier Conjugués anticorps-médicament anti-cd7 et leurs procédés d'utilisation
WO2025111450A1 (fr) 2023-11-22 2025-05-30 Les Laboratoires Servier Conjugués anticorps anti-cd74-médicament et leurs procédés d'utilisation
WO2025126157A1 (fr) 2023-12-15 2025-06-19 Advesya Domaines de liaison anti-il-1rap et conjugués anticorps-médicament associés
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025245003A1 (fr) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6042820A (en) 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6472375B1 (en) 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
US7750004B2 (en) * 2005-07-07 2010-07-06 Abbott Laboratories Apoptosis promoters
EP3243814B1 (fr) 2007-04-16 2018-10-17 AbbVie Inc. Indole 7 substitué en tant qu'inhibiteurs de mcl-1
EP2185562B1 (fr) * 2007-07-27 2015-12-02 Janssen Pharmaceutica, N.V. Pyrrolopyrimidines utiles dans le traitement de maladies proliferatives
US8975286B2 (en) * 2009-08-20 2015-03-10 Merck Sharp & Dohme Corp. Ether benzotriazole derivatives
AU2010303324A1 (en) * 2009-10-08 2012-04-05 Sanford-Burnham Medical Research Institute Apogossypolone derivatives as anticancer agents
JP5937968B2 (ja) * 2010-01-29 2016-06-22 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｍｃｌ‐１を調節する小分子、並びに細胞死、細胞分裂、細胞分化を調節する方法、及び疾患を治療する方法。
WO2013052943A2 (fr) 2011-10-06 2013-04-11 The Regents Of The University Of Michgian Inhibiteurs à petite molécule de mcl-1 et leurs utilisations
WO2013149124A1 (fr) * 2012-03-29 2013-10-03 The Regents Of The University Of Michigan Inhibiteurs de mcl-1 à petite molécule et utilisations de ceux-ci
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1
WO2017147410A1 (fr) 2016-02-25 2017-08-31 Amgen Inc. Composés inhibant la protéine mcl-1

Also Published As

Publication number Publication date
SG11201701525WA (en) 2017-03-30
SMT201900048T1 (it) 2019-02-28
US20230271981A1 (en) 2023-08-31
IL257942A (en) 2018-05-31
EA031223B1 (ru) 2018-12-28
KR102466351B1 (ko) 2022-11-10
IL257942B (en) 2020-05-31
CN107001387A (zh) 2017-08-01
TW201625645A (zh) 2016-07-16
LT3186259T (lt) 2019-02-25
PH12017500367B1 (en) 2017-07-10
TR201901312T4 (tr) 2019-02-21
US11001598B2 (en) 2021-05-11
CO2017002998A2 (es) 2017-07-19
JP2017525730A (ja) 2017-09-07
JP6502479B2 (ja) 2019-04-17
MX379155B (es) 2025-03-11
CA2959615A1 (fr) 2016-03-03
TWI676628B (zh) 2019-11-11
US20170088560A1 (en) 2017-03-30
US10100063B2 (en) 2018-10-16
ES2777478T3 (es) 2020-08-05
US10836779B2 (en) 2020-11-17
PT3186259T (pt) 2019-02-06
PE20170892A1 (es) 2017-07-12
ZA201701763B (en) 2018-08-29
MX2017002656A (es) 2017-10-12
AU2015308735B2 (en) 2019-03-14
UY36285A (es) 2016-04-01
US20190023720A1 (en) 2019-01-24
CL2017000469A1 (es) 2017-11-03
US20190016736A1 (en) 2019-01-17
DK3186259T3 (en) 2019-02-25
ME03313B (fr) 2019-10-20
KR20170043661A (ko) 2017-04-21
EP3186259A1 (fr) 2017-07-05
MY176235A (en) 2020-07-24
US10494381B2 (en) 2019-12-03
EP3424931A3 (fr) 2019-02-20
AU2015308735A1 (en) 2017-03-23
EP3186259B1 (fr) 2018-12-19
US11685747B2 (en) 2023-06-27
RS58276B1 (sr) 2019-03-29
UA118233C2 (uk) 2018-12-10
BR112017004209A2 (pt) 2018-07-31
NZ729768A (en) 2021-06-25
PH12017500367A1 (en) 2017-07-10
PL3186259T3 (pl) 2019-04-30
ZA201802865B (en) 2022-05-25
TN2017000067A1 (en) 2018-07-04
CA2959615C (fr) 2023-01-17
ES2706309T3 (es) 2019-03-28
JO3474B1 (ar) 2020-07-05
IL250843B (en) 2018-03-29
HUE041806T2 (hu) 2019-05-28
US20160068545A1 (en) 2016-03-10
US20210040120A1 (en) 2021-02-11
CR20170116A (es) 2017-04-28
US12024529B2 (en) 2024-07-02
EP3424931B1 (fr) 2020-02-12
US9562061B2 (en) 2017-02-07
CY1121195T1 (el) 2020-05-29
CN107001387B (zh) 2019-03-05
MA40111B1 (fr) 2018-12-31
US20200062780A1 (en) 2020-02-27
EA201790492A1 (ru) 2017-07-31
SI3186259T1 (sl) 2019-03-29
AP2017009827A0 (en) 2017-03-31
AR101729A1 (es) 2017-01-11
BR112017004209B1 (pt) 2022-08-09
HRP20190053T1 (hr) 2019-02-22
WO2016033486A1 (fr) 2016-03-03
EP3424931A2 (fr) 2019-01-09
IL250843A0 (en) 2017-04-30

Similar Documents

Publication Publication Date Title
MA40111A1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA53399B1 (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
MA39783B1 (fr) Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase
MA40225A (fr) Composés dihydroisoquinolinone substitués
MA39898B1 (fr) Composés 4-amino-imidazoquinoline
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA42410B1 (fr) Oxystérols et leurs méthodes d'utilisation
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA44674A (fr) Inhibiteurs de bromodomaine
MA40768A (fr) Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA43052B1 (fr) Inhibiteurs de la kallicréine plasmatique humaine
EA201690077A1 (ru) Терапевтически активные производные эстратриен-тиазола
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA44079B1 (fr) Compositions pharmaceutiques comprenant un dérivé de phénylaminopyrimidine
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA42769B1 (fr) Dérivés de fluoroindole en tant que modulateurs allostériques positifs du récepteur muscarinique m1
MA41174B1 (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
MA39926B1 (fr) Dérivés de dihétérocycle liés à cycloalkyle
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques